Steroids for rheumatoid arthritis: The honeymoon revisited (once again)

Journal of Rheumatology

Volumn 32, Issue 10, 2005, Pages 1863-1865

  Caplan, Liron ^a   Russell, Anthony S ^b   Wolfe, Frederick ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; STEROID;

CLINICAL TRIAL; COMORBIDITY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG EFFICACY; DRUG POTENCY; EDITORIAL; FRACTURE; HUMAN; LOW DRUG DOSE; META ANALYSIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS; SYSTEMATIC REVIEW; TOXICITY; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; PROFESSIONAL PRACTICE; RHEUMATOLOGY; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 26444573183     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (26)

1. Kroot EJA, van Leeuwen MA, van Rijswijk MH, et al. No increased mortality in patients with rheumatoid arthritis: up to 10 years of follow up from disease onset. Ann Rheum Dis 2000;59:954-8.
2. Wolfe F, Michaud K. Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 2004;31:695-700.
3. Zink A, Listing J, Niewerth M, Zeidler H. The national database of the German Collaborative Arthritis Centres: II. Treatment of patients with rheumatoid arthritis. Ann Rheum Dis 2001;60:207-13.
4. Gotzsche PC, Johansen HK. Meta-analysis of short-term low dose prednisolone versus placebo and non-steroidal anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998;316:811-8.
5. Criswell LA, Saag KG, Sems KM, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 2, 2004. Chichester, UK: John Wiley & Sons, Ltd.
6. Rau R, Wassenberg S, Zeidler H for the LDPT-Study Group. Low dose prednisolone therapy (LDPT) retards radiographically detectable destruction in early rheumatoid arthritis -preliminary results of a multicenter, randomized, parallel, double blind study. Z Rheumatol 2000;59:90-6.
7. Kirwan JR and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995;333:142-6.
8. Van Everdingen AA, Jacobs JWG, van Reesema DRS, Bijlsma WJ. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo controlled clinical trial. Ann Intern Med 2002;136:1-12.
9. Capell HA, Madhok R, Hunter JA, et al, on behalf of the WOSERACT Group. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. Ann Rheum Dis 2004;63:797-803.
10. Hickling P, Jacoby RK, Kirwan JR, and the Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. Joint destruction after glucocorticoids are withdrawn in early rheumatoid arthritis. Br J Rheumatol 1998;37:930-6.
11. Laan RFJM, van Riel PLCM, van de Putte LBA, van Erning LJTO, van't Hof MA, Lemmens JAM. Low-dose prednisone induces rapid reversible axial bone loss in patients with rheumatoid arthritis. Ann Intern Med 1993;119:963-8.
12. Hansen M, Podenphant J, Florescu A, et al. A randomized trial of differentiated prednisolone treatment in active rheumatoid arthritis: clinical benefits and skeletal side effects. Ann Rheum Dis 1999;58:713-8.
13. Million R, Poole P, Kellgren JH, Jayson MI. Long-term study management of rheumatoid arthritis. Lancet 1984;1:812-6.
14. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
15. Buttgereit F, Straub RH, Wehling M, Burmester G. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum 2004;50:3408-17.
16. Van Staa T, Leufkens H, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000;15:993-1000.
17. Davis JM, Maradit-Kremers H, Gabriel SE. Use of low-dose glucocorticoids and the risk of cardiovascular morbidity and mortality in rheumatoid arthritis: What is the true direction of effect? J Rheumatol 2005;32:1856-62.
18. Concato J. Observational versus experimental studies: what's the evidence for a hierarchy? NeuroRx 2004;1:341-7.
19. Feinstein AR. Clinical biostatistics. XX. The epidemiologic trohoc, the ablative risk ratio, and "retrospective" research. Clin Pharmacol Ther 1973;14:291-307.
20. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of pneumonia: associations with prednisone, DMARDs and anti-TNF Therapy. Arthritis Rheum 2005; (in press).
21. Criswell LA, Henke CJ. What explains the variation among rheumatologists in their use of prednisone and second-line agents for the treatment of rheumatoid arthritis? J Rheumatol 1995;22:829-35.
22. Lacaille D, Anis AH, Guh DP, Esdaile JM. Gaps in care for rheumatoid arthritis: A population study. Arthritis Care Res 2005;53:241-8.
23. Goldsmith CH. Report of the 5th Joint WHO/ILAR Taskforce Meeting on Rheumatic Diseases. Geneva: WHO/OMS; 1993.
24. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001;345:941-7.
25. Song I-H, Gold R, Straub RS, Burmester G-R, Buttgereit F. New glucocorticoids on the horizon: Repress, don't activate! J Rheumatol 2005;32:1199-207.
26. ACR Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002;46:328-46.